Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and augmented intelligence to help physicians identify the location of chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. The move comes as the company reports triple-digit growth in utilization of its Nociscan platform and seeks to deepen adoption in a key strategic region.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. In his new role, Keefe will lead commercial efforts across the Western U.S., building on Aclarion's existing footprint with academic institutions and high-volume private practice spine centers.
"Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies," said Brent Ness, CEO of Aclarion. "His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan."
Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It uses Magnetic Resonance Spectroscopy data from an MRI machine to quantify chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
An estimated 266 million people worldwide live with chronic low back pain, making it one of the most pervasive health challenges. Aclarion's appointment of Keefe signals its commitment to expanding access to Nociscan as demand grows. "I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community," said Keefe. "The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated."
The expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization. Aclarion's focus on the Western U.S. is part of a broader strategy to integrate Nociscan into clinical practice at leading spine centers. For more information about Aclarion and Nociscan, visit www.aclarion.com.
